A member of the Chinese Academy of Medical Sciences, The Institute of Materia Media (IMM) have entered into a joint research partnership with the Global Alliance for TB Drug Development (TB Alliance) to develop promising, novel anti-tuberculosis drugs.
The said alliance wil focus on the desin, synthesis and evaluation of riminophenazines (a class of anti-TB compounds discovered in the 1950s) and do deliver compounds from this class without the side effects.
According to Dr. Maria C. Freire, CEO and President of the TB Alliance:
"Developing faster and better TB drugs is literally a matter of life and death, and this partnership is an important step forward. By bringing together the best science in China with the TB Alliance's expertise and commitment to affordability and access, we are helping to advance and expand the TB drug pipeline."Find more details from the full report.
Comment Preview